ライフサイエンスコーパス: TARC

1 TARC, MDC, and SDF-1 increased intracellular calcium con

2 TARC, which also induced calcium mobilization in CCR4 tr

3 inducible expression of CC (I-309, Exodus-1, TARC, RANTES, MCP-1, MDC, and MIP-1 alpha and -1 beta),

4 accharide (LPS)-induced production of MCP-1, TARC, and MDC by DCs was clearly enhanced.

5 10, 13, 17 A, Eotaxin, GM-CSF, IFNy, MCP-1, TARC, TNFalpha, Total IgE, and Endotoxin) were quantifie

6 iated cytokines and chemokines (IL-5, IL-13, TARC/CCL17), but not IFN-gamma levels, significantly cor

7 -regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22)

8 ulinemia and elevated levels of serum IL-18, TARC and fecal EDN.

9 13, IL-16, IP-10, MCP-1, MCP-4, MDC, MIP-1a, TARC, TNFB) was associated with diminished quality of li

10 ibart rapidly downregulated IL-4, IL-13, and TARC gene expression, with greater effectiveness than du

11 IL-17A and TARC/CCL17 were significantly augmented in patients that

12 MDC (macrophage-derived chemokine/CCL22) and TARC (thymus and activation-regulated chemokine/CCL17),

13 dko mice involving eotaxin, MARC (CCL7), and TARC (CCL17).

14 Our results suggest that CCR4 and TARC are important in the recognition of skin vasculatur

15 s to generate chemokines such as eotaxin and TARC.

16 Since MDC and TARC are both expressed in the thymus, one role for thes

17 In addition, the genes for MDC and TARC are encoded by human chromosome 16.

18 MDC and TARC competed for binding to CCR4, while no binding comp

19 Both MDC and TARC functioned as chemoattractants for CCR4 transfectan

20 dy that CCR4 is a major receptor for MDC and TARC on T lymphocytes, as anti-CCR4 mAbs significantly i

21 The MDC and TARC receptor CCR4 was expressed on platelets, and an an

22 s the secretion of the CC-chemokines MDC and TARC.

23 R4, the common specific receptor for MDC and TARC.

24 ibit the migration of these cells to MDC and TARC.

25 r, chemokine release (e.g. MCP-1, RANTES and TARC) was significantly reduced in inhibitor-treated mic

26 1.6 and 9.7 +/- 0.8 ng/mL, respectively) and TARC production in PBMCs (IC(50): 59.2 +/- 3.9 and 13.5

27 TSLP and TARC/CCL17 expression correlated with airway obstruction

28 Immunohistochemistry reveals anti-TARC reactivity of venules and infiltration of many CCR4

29 cellular provenance of TSLP, Th2-attracting (TARC/CCL17, MDC/CCL22, I-309/CCL1), and Th1-attracting (

30 , disease severity-related serum biomarkers (TARC, PARC, periostin, and IL-22), eotaxin-1, and eotaxi

31 CCR4 antibody blocked aggregation induced by TARC or MDC.

32 Trafficking of monocytes is mediated by TARC (CCL17) and associates with viral load measured in

33 emokine production of CCL22 (MDC) and CCL17 (TARC), two chemokines previously shown to be important i

34 ation of CXCL10 (IP-10), CCL22 (MDC), CCL17 (TARC), CCL-2 (MCP-1) and CCL-13 (MCP-4) in both asthma g

35 wed preferential T(H)2 skewing (IL-13, CCL17/TARC, and CCL18), whereas psoriasis was characterized by

36 wed preferential T(H)2 skewing (IL-13, CCL17/TARC, and CCL18), whereas psoriasis was characterized by

37 (H)9 axis with increased CCL22/MDC and CCL17/TARC serum levels.

38 We furthermore show that the chemokine CCL17/TARC, but not CCL27/CTACK, was sufficient to induce the

39 IL-4, IL-5, and IL-13) and chemokines (CCL17/TARC, CCL5/RANTES [regulated upon activation, normal T-c

40 relation exists among CCR4, its ligand CCL17/TARC, and the cutaneous lymphocyte-homing process.

41 ngs demonstrate that RSV induces a chemokine TARC that has the potential to recruit Th2 cells to the

42 he thymus and activation-regulated chemokine TARC, were unchanged.

43 e cytokine responses, and altered chemokine (TARC and CCL17) responses.

44 thymus- and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC)), CD (10 pr

45 s thymus and activation-regulated chemokine (TARC) and macrophage-derived chemokine (MDC).

46 m thymus and activation-regulated chemokine (TARC) levels may be a potential biomarker to diagnose so

47 Thymus- and activation-regulated chemokine (TARC) recruits Th2 cells to sites of inflammation.

48 , thymus and activation-regulated chemokine (TARC) stands out and can indeed serve as a biomarker of

49 , thymus and activation-regulated chemokine (TARC), and I-309] and two RNases (angiogenin and RNase 4

50 MDC), thymus activation-regulated chemokine (TARC), and stromal cell-derived factor one (SDF-1) are h

51 , thymus and activation-regulated chemokine (TARC), and TSLP were measured at baseline and over 52 we

52 , thymus and activation regulated chemokine (TARC), eotaxin, and eotaxin-2 acted specifically on in v

53 d thymus and activation-regulated chemokine (TARC), has been implicated as a preferential marker for

54 , thymus and activation-regulated chemokine (TARC), IL-8, monocyte chemoattractant protein-1 (MCP-1),

55 m thymus and activation-regulated chemokine (TARC), plasma eotaxin-3, serum total immunoglobulin E (I

56 , thymus and activation-regulated chemokine (TARC), soluble interleukin 6 receptor (sIL-6R), and solu

57 thymus- and activation-regulated chemokine (TARC), which contains 37% identical amino acids.

58 n thymus and activation-regulated chemokine (TARC)/CC chemokine ligand 17 (CCL17), total IgE, lactate

59 (thymus and activation-regulated chemokine (TARC)/CCL17, macrophage-derived chemokine (MDC)/CCL22, I

60 f Thymus and Activation-Regulated Chemokine (TARC/CCL17) and interleukin (IL)-5 and an increase in IP

61 Thymus- and activation-regulated chemokine (TARC/CCL17) was slightly higher in children who develope

62 e thymus and activation-regulated chemokine (TARC; CCL17) is displayed by cutaneous (but not intestin

63 L12), thymus activation regulated chemokine (TARC; or CCL17), and macrophage-derived chemokine (MDC;

64 nd thymus- and activation-related chemokine (TARC) by DCs.

65 C), thymus and activation-related chemokine (TARC), C10), and d) constitutive (lungkine, secondary ly

66 he thymus- and activation-related chemokine (TARC).

67 , thymus and activation-regulated chemokine [TARC] and eotaxin-3).

68 r thymus and activation regulated chemokine; TARC) and CCL22 (or macrophage-derived chemokine; MDC),

69 roduction of the T(H)2-attracting chemokines TARC (thymus and activation-regulated chemokine; also kn

70 efore respond to its ligands, the chemokines TARC and MDC.

71 ptosis and cell migration toward chemokines (TARC/CCL17, IP-10).

72 ated temperature-adaptive radiative coating (TARC) optimally absorbs the solar energy and automatical

73 In contrast, TARC, MCP-1, and MDC were not induced, suggesting the ex

74 ted with GITR: Fc FP confirmed corresponding TARC and MCP-1 protein production by keratinocytes.

75 ed serum IgE levels, blood eosinophil count, TARC, eotaxin-3 and FeNO in patients both with and witho

76 tterns, improved radiation coverage, low ECC/TARC, and sufficient channel capacity.

77 The corresponding receptors for eotaxin, TARC, and IP-10 are also differentially expressed on Th1

78 In desensitization Ca flux experiments, TARC and STCP-1 bound to a common receptor and therefore

79 ed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay.

80 se data suggest a positive feedback loop for TARC production between RSV infection and Th2 cytokines.

81 (CCR4), recently shown to be a receptor for TARC.

82 Staining for TARC was present on lacrimal gland ductular cells but no

83 ater median percent reductions at week 16 in TARC/CCL17 (-83.3% to -72.4% vs -14.9% to -1.8%), total

84 t, median percentage change from baseline in TARC levels ranged from -24.8% to -88.6% (placebo +2.6%

85 acute RSV infection of BALB/c mice increased TARC production in the lung.

86 After RSV infection, TARC production significantly increased in the vaccinia

87 Moreover, vorino-stat inhibited TARC secretion by dendritic cells that were activated by

88 metalloproteinases 2 and 9, chemokines (KC, TARC), and cytokines (IFN-gamma) seen in bronchoalveolar

89 Cells expressing the CCR4 ligand TARC (thymus- and activation-regulated chemokine) were d

90 The chemokines Mig (CXCR3 ligand), TARC (CCR4 ligand), and MCP-2 (CCR5 ligand) were detecte

91 abundant expression of the two CCR4 ligands TARC/CCL17 and MDC/CCL22.

92 ytes express CCR4 and respond to its ligands TARC and MDC, whereas Th1 lymphocytes express CXC chemok

93 e expression pattern of CCR4 and its ligands TARC/CCL17 and MDC/CCL22 in the peripheral blood and ski

94 ith higher sCD163 and IL-10 levels but lower TARC levels.

95 se findings suggest that the chemokines MDC, TARC, and SDF-1, which may be produced during inflammato

96 We measured TARC levels in prediagnostic serum samples and found str

97 Circulating eosinophils, monocytes, TARC, MCP-4, IL-16 and allergen-specific IgE levels were

98 Moreover, TARC induces integrin-dependent adhesion of skin (but no

99 by killing CCR4(+) cells through delivery of TARC-fused toxins or depleting Tregs and preventing lung

100 ry pads activates remotely the expression of TARC/CCL17 and MDC/CCL22 in the lungs.

101 The levels of TARC, CTACK, IL-8, IL-18 showed significant correlation

102 to-severe AD significantly reduced levels of TARC/CCL17, total IgE, and LDH to levels comparable with

103 rated a marked increase in the production of TARC.

104 synergistic effect of RSV and IL-4/IL-13 on TARC production reflected differential induction of NF k

105 or serum total IgE, IL-5, IL-13, periostin, TARC, or TSLP, when these biomarkers were assessed indiv

106 ve patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS.

107 The disease severity-associated proteins TARC/CCL17 and PARC/CCL18 decreased during treatment, an

108 so adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with sh

109 Serum TARC levels at 6 and 24 h after antigen ingestion were c

110 Serum TARC may be related to the part of gastrointestinal food

111 -tested negative milk-specific IgE and serum TARC levels (2210 pg/mL).

112 elationship between FPIES severity and serum TARC levels.

113 relation between vomiting duration and serum TARC levels.

114 ere was a moderate correlation between serum TARC levels and vomiting duration.

115 CD4(+) and/or clonal T cells, elevated serum TARC/CCL17, soluble (s)CD25, and/or detectable IL-5 were

116 Post-emetic serum TARC correlates with the severity of FPIES.

117 gative milk-specific IgE and very high serum TARC levels (25200 pg/mL) at the time of onset.

118 ipheral eosinophilia (5820 /muL), high serum TARC levels (4730 pg/mL) and positive milk-specific IgE

119 al eosinophilia (2923 /muL), very high serum TARC levels (49100 pg/mL) and positive milk-specific IgE

120 Reductions in serum TARC, plasma eotaxin-3 and serum periostin occurred rapi

121 We measured serum TARC (Thymus and activation-regulated chemokine, CCL-17)

122 The median serum TARC (pg/ml) in the asymptomatic, mild-moderate, and sev

123 k-specific IgE (0.42 UA/mL) and normal serum TARC levels (1250 pg/mL).

124 negative milk-specific IgE and normal serum TARC levels (198 pg/mL).

125 The serum TARC level was significantly higher in the symptomatic e

126 a beta-ribofuranoside of TAP, which we term TARC.

127 in infants who later developed AD, and that TARC/CCL17 levels were higher.

128 memory T cells, which uniformly express the TARC receptor CC chemokine receptor (CCR)4.

129 regulatory T cells (Tregs) that express the TARC/MDC-specific chemokine receptor CCR4, thus generati

130 me 16q13, the same position reported for the TARC gene.

131 IL-13, p = 0.20), and similar potency in the TARC assays.

132 nd STAT6 by the two stimuli (both are in the TARC promoter).

133 After therapy TARC, MDC, and IL-10 correlated with PFS and overall sur

134 In line with this, TARC/CCL17 (a CCR4 ligand) induces preferential chemotax

135 ectin ligand+ T cells migrate efficiently to TARC and to CTACK.

136 fully desensitized a subsequent response to TARC.

137 robust chemotactic and adhesive responses to TARC, consistent with a selective role for CCR4 in skin

138 Cells expressing mRNA encoding TSLP, TARC/CCL17, MDC/CCL22, and IP-10/CXCL10, but not I-TAC/C

139 lium and submucosa expressing mRNA for TSLP, TARC/CCL17, MDC/CCL22, and IP-10/CXCL10, but not I-TAC/C

140 Our data implicate TSLP, TARC/CCL17, MDC/CCL22, and IP-10/CXCL10 in asthma pathog

141 ukin (IL)-1a, IL-1B, IL-8, IL-18) along with TARC and CTACK in tape strips.

142 L)-1alpha, IL-1beta, IL-8, IL-18) along with TARC and CTACK in tape strips.

143 the asthmatic biopsies which correlated with TARC and MDC expression and airway obstruction.